BioVie's (BIVI) NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall St indexes climb as US, Iran halt attacks; Comcast surges on spin-off plan
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- Strategy stock jumps 7% as firm shifts to active capital management
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Dat
March 1, 2024 8:00 AM ESTData from Phase 2a trial in Parkinsons Disease suggest patients treated with NE3107 experienced significant improvements in non-motor symptoms and motor control while placebo-treated patients worsened
Data from Phase 3 trial in mild to moderate Alzheimers Disease suggest NE3107 may have the potential to realign physiological processes in patients consistent with decreased neurocognitive decline and diseases of aging
CARSON CITY, Nev., March 01, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (BioVie or the Company) a clinical-stage company developing innovative drug therapies for the... More
